Intravenous LD50s (mg/kg): mice, 287; rats, 329.
Signs and Symptoms
Inadvertent administration of an overdose or inadvertent intravenous bolus administration/rapid intravenous infusion may be associated with hypotension, tachycardia and gastrointestinal disturbances; acute but transient loss of vision, aphasia, agitation, headache, nausea, pallor, CNS depression including coma, bradycardia and acute renal failure have been reported.
Acute respiratory distress syndrome has been reported following treatment with excessively high intravenous doses of Desferal in patients with acute iron intoxication and in patients with thalassemia.
There is no specific antidote. Desferal should be discontinued and appropriate symptomatic measures undertaken.
Desferal is readily dialyzable.
Known hypersensitivity to the active substance.
Desferal is contraindicated in patients with severe renal disease or anuria, since the drug and the iron chelate are excreted primarily by the kidney. (See WARNINGS).
Last reviewed on RxList: 1/5/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Desferal Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.